bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Down 36.0% in July

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totaling 522,561 shares, a decrease of 36.0% from the June 30th total of 816,644 shares. Based on an average daily trading volume, of 589,484 shares, the days-to-cover ratio is presently 0.9 days. Approximately 11.3% of the shares of the company are short sold.

bioAffinity Technologies Stock Performance

BIAF traded down $0.02 on Thursday, reaching $0.57. The stock had a trading volume of 30,876 shares, compared to its average volume of 3,949,597. The business’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $1.68. The company has a market cap of $2.68 million, a P/E ratio of -0.05 and a beta of -1.11. bioAffinity Technologies has a 12-month low of $0.56 and a 12-month high of $13.50. The company has a current ratio of 1.36, a quick ratio of 1.34 and a debt-to-equity ratio of 0.15.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($2.40) by $1.59. The firm had revenue of $1.35 million during the quarter, compared to analyst estimates of $1.48 million. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Geode Capital Management LLC purchased a new position in shares of bioAffinity Technologies during the 4th quarter valued at approximately $36,000. Scientech Research LLC purchased a new stake in bioAffinity Technologies in the 3rd quarter worth $49,000. Finally, J. Safra Sarasin Holding AG purchased a new stake in bioAffinity Technologies in the 1st quarter worth $164,000. 1.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BIAF has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. Wall Street Zen upgraded bioAffinity Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.